Vera Therapeutics (NASDAQ:VERA – Get Free Report) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.34) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.
Vera Therapeutics Stock Performance
NASDAQ:VERA opened at $42.85 on Wednesday. The company has a market capitalization of $3.00 billion, a PE ratio of -10.74 and a beta of 1.16. The company has a 50 day simple moving average of $47.28 and a two-hundred day simple moving average of $34.46. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $56.05.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on VERA. Wedbush increased their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Friday, November 28th. Evercore raised their target price on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Finally, JPMorgan Chase & Co. dropped their price target on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $77.18.
Insider Activity
In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the stock in a transaction on Thursday, December 11th. The shares were purchased at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the acquisition, the director owned 5,882 shares in the company, valued at approximately $249,985. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 16.30% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Vera Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in VERA. Price T Rowe Associates Inc. MD lifted its position in Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after acquiring an additional 1,795,537 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares in the last quarter. Armistice Capital LLC boosted its position in shares of Vera Therapeutics by 294.1% during the third quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock valued at $15,576,000 after buying an additional 400,000 shares during the last quarter. Millennium Management LLC grew its holdings in Vera Therapeutics by 173.5% during the third quarter. Millennium Management LLC now owns 598,454 shares of the company’s stock worth $17,391,000 after buying an additional 379,623 shares in the last quarter. Finally, First Light Asset Management LLC raised its position in Vera Therapeutics by 71.5% in the 4th quarter. First Light Asset Management LLC now owns 869,676 shares of the company’s stock valued at $44,040,000 after buying an additional 362,579 shares during the last quarter. 99.21% of the stock is owned by institutional investors.
Vera Therapeutics Company Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- Energy Security Is Now National Security – Positioning Is Happening Now
- The gold chart Wall Street is terrified of…
- The “Bomb” in America’s Basement
- Unlocked: Elon Musk’s Next Big IPO
- How to collect $1,170 a month from silver
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
